Agilent Technologies Completes Biocare Medical Acquisition

Key Facts

1Agilent Technologies has completed its acquisition of Biocare Medical, a leader in clinical pathology.

Agilent Technologies has completed its acquisition of Biocare Medical, a leader in clinical pathology, according to a Business Wire report. The acquisition is part of the company's strategy to expand its pathology offerings.

The company expects the acquisition to be accretive to growth, margins, and non-instrument revenue within 12 months, per the announcement. Agilent shares closed at $131.63 on June 24, 2026, with a daily range of $128.25–$132.72. Investors will monitor integration progress and the impact on quarterly results as the company leverages Biocare's clinical pathology expertise.